Comparative analysis of the main clinical features of Henoch–Schönlein purpura in previous studies
| First author | Country year | Patients (n) | Prosp./retros. | Mean age (range/SD) | Boys (%) | Skin manifestation | Joint manifestation | GI manifestation | Renal manifestation | Recurrences | References |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Present study | Finland 2008 | 223 | Prosp. | 7.1 years 1.6–16.7 years | 55 | 223/223 (100%) | 200/221 (90%) | 126/221 (57%) | 102/221 (46%) | 55/221 (25%) | |
| Al-Sheyyab | Jordan 1999 | 48 | Prosp. | 6.5 years 1.6–13 years | 40 | NA | NA | NA | 22/48 (46%) | NA | 7 |
| Fretzayas | Greece 2008 | 74 | Prosp. | 5.2 years 1.5–13 years | 55 | 73/74 (99%) | 68/74 (92%) | 46/74 (62%) | 19/74 (26%) | 49/74 (66%) | 13 |
| Huber | Canada 2004 | 40 | Prosp. | NA 2–15 | NA | 40/40 (100%) | 38/40 (95%) | 39/40 (98%) | NA | 6/40 (15%) | 11 |
| Muslu | Turkey 2002 | 30 | Prosp. | 9.7 years 3.5–16 years | 57 | 30/30 (100%) | 25/30 (83%) | 8/30 (27%) | 13/30 (43%) | NA | 20 |
| Total 415 | |||||||||||
| Mean | 6.9 years | 53 | 100% | 91% | 60% | 42% | 36% | ||||
| Range | 30–223 | 1.5–16.7 years | 40–57 | 99–100% | 83–95% | 27–98% | 26–46% | 15–66% | |||
| Allen | Allen 1960 | 131 | Retros. | 4 years 0.5–16 years | 64 | 131/131 (100%) | 89/131 (68%) | 69/131 (53%) | 53/131 (40%) | NA | 2 |
| Balmelli | Switzerland 1996 | 139 | Retros. | 5.4 years 0.4–15.1 years | 58 | 139/139 (100%) | 110/139 (79%) | 92/139 (66%) | 60/139 (43%) | 10/139 (7%) | 15 |
| Blanco | Spain 1997 | 116 | Retros. | 6.9+/-3.1 years | 66 | 116/116 (100%) | 93/116 (80%) | 74/116 (64%) | 29/116 (25%) | NA | 21 |
| Calvino | Spain 2001 | 78 | Retros. | 6.2 years 1–13 years | 46 | 78/78 (100%) | 61/78 (78%) | 57/78 (73%) | 42/78 (54%) | 10/69 (15%) | 6 |
| Chang | Taiwan 2004 | 261 | Retros. | 6.9 years 1–20 years | 53 | 261/261 (100%) | 112/261 (43%) | 151/261 (58%) | 53/261 (20%) | NA | 12 |
| Fischer | Germany 1990 | 119 | Retros. | 6.4 years 1–17 years | 54 | 119/119 (100%) | 91/119 (76%) | 90/119 (76%) | 64/119 (54%) | NA | 14 |
| Hamdan | Jordan 2008 | 68 | Retros. | 5.9 years 1–13 years | 59 | 68/68 (100%) | 51/68 (75%) | 43/68 (63%) | 20/68 (29%) | 14/68 (21%) | 22 |
| Kaku | Japan 1998 | 194 | Retros. | 6.3 years 1.5–14.5 years | 50 | 194/194 (100%) | 140/194 (72%) | 111/194 (57%) | 65/194 (34%) | NA | 23 |
| Nong | Taiwan 2007 | 107 | Retros. | 6.2 years 2–13 years | 59 | 102/107 (95.3%) | 50/107 (47%) | 77/107 (72%) | 30/107 (28%) | NA | 17 |
| Peru | Turkey 2008 | 254 | Retros. | 8.65±3.59 years | 58 | 254/254 (100%) | 168/254 (66%) | 142/254 (56%) | 76/254 (76%) | NA | 24 |
| Potts | UK 1987 | 133 | Retros. | 6 years 1–13 years | 60 | 132/133 (99%) | 107/133 (80%) | 73/133 (56%) | 52/133 (40%) | NA | 25 |
| Prais | Israel 2007 | 260 | Retros. | 5.7 years 1–14.8 years | 57 | 260/260 (100%) | 177/260 (68%) | 153/260 (59%) | 91/260 (35%) | 7/260 (3%) | 26 |
| Rigante | Italy 2005 | 94 | Retros. | 6.3 years 3–14 years | 49 | 94/94 (100%) | 64/94 (68%) | 57/94 (61%) | 13/74 (18%) | 9/74 (12%) | 27 |
| Sano | Japan 2001 | 134 | Retros. | 6.3 years 2–15 years | 53 | 134/134 (100%) | 99/134 (74%) | 96/134 (72%) | 65/134 (49%) | NA | 28 |
| Shin | Korea 2006 | 206 | Retros. | 7.2±2.8 years | 55 | 206/206 (200%) | 129/206 (63%) | 108/206 (52%) | 78/206 (38%) | 52/206 (25%) | 29 |
| Saulsbury | USA 1999 | 100 | Retros | 5.9 (1–15) years | 57 | 100/100 (100%) | 82/100 (82%) | 63/100 (63%) | 40/100 (40%) | 33/100 (33%) | 4 |
| Trapani | Italy 2005 | 150 | Retros. | 6.1±2.7 years | 63 | 150/150 (100%) | 111/150 (74%) | 77/150 (51%) | 81/150 (54%) | 41/118 (35%) | 3 |
| Total 2544 | |||||||||||
| Mean | 6.4 years | 56 | 100% | 68% | 60% | 36% | 17% | ||||
| Range | 68–260 | 0.4–20 years | 46–66 | 95–100% | 43–82% | 51–76% | 18–76% | 3–35% |
GI, gastrointestinal; NA, not available; Prosp., prospective; Retros., retrospective.